Prostatype Genomics AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 0.109755 million compared to SEK 0.426442 million a year ago. Revenue was SEK 0.109765 million compared to SEK 0.426442 million a year ago. Net loss was SEK 7.98 million compared to SEK 3.66 million a year ago.
For the nine months, sales was SEK 0.378477 million compared to SEK 1.77 million a year ago. Revenue was SEK 0.378484 million compared to SEK 1.79 million a year ago. Net loss was SEK 20.93 million compared to SEK 9.88 million a year ago.